Abstract
A more effective use of antibody in treating cancer appears to require derivatives with enhanced cytotoxic potential. Working with anti-idiotype antibodies directed against neoplastic lymphocytes, we have shown previously that univalent antibody derivatives with intact Fc-regions can avoid antigenic modulation while retaining the ability to recruit cytotoxic effectors such as complement. Chimeric univalent antibodies represent an extension of this approach. To prepare them Fab′γ from antibody is linked by thioether bonds to half-cystine in normal Ig of the species to undergo immunotherapy. The derivatives FabIgG and FabFc utilize IgG and Fcγ respectively as the effector partners of the antibody Fab′γ. They appear superior to parent antibody in their ability to invoke complement and K-cell killing of target lymphocytes. They show promise of being minimally immunogenic and, because they present homologous Fc, should prove efficient recruiters of host effector functions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Levy R, Miller R A: Biological and clinical implications of lymphocyte hybridomas.Ann Rev Med 34, 107 (1983).
Rosenberg S A, Terry W D: Passive immunotherapy of cancer in animals and men.Adv Cancer Res 25, 323 (1977).
Hamblin T J, Abdul-Ahad A K, Gordon J, Stevenson F K, Stevenson G T: Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces.Br J Cancer 42, 495 (1980).
Miller R A, Maloney D G, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.New Engl J Med 306, 517 (1982).
Boyse E A, Old L J: Some aspects of normal and abnormal cell surface genetics.Ann Rev Genet 3, 269 (1969).
Gordon J, Stevenson G T: Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relationship to redistribution of the antigen.Immunology 42, 13 (1981).
Ritz J, Schlossman S F: Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.Blood 59, 1 (1982).
Glennie M J, Stevenson G T: Univalent antibodies kill tumour cellsin vitro andin vivo.Nature 295, 712 (1982).
Stevenson G T, Glennie M J, Gordon J: The killing of lymphoma cells by univalent derivatives of tumorspecific an antibody.UCLA Symp Molec Cell Biol 24, 459 (1982).
Stevenson G T, Smith J L, Hamblin T J:Immunological Investigation of Lymphoid Neoplasms, pp. 41–46. Edinburgh, Churchill Livingstone (1983).
Stanworth D R, Turner M W: Immunochemical analysis of immunoglobulins and their subunits, in Weir D M (ed).Handbook of Experimental Immunology, vol. 1, chap. 6. Oxford, Blackwell Scientific Publications (1978).
Yoshitake S, Hamaguchi Y, Ishikawa E: Efficient conjugation of rabbit Fab′ with β-D-galactosidase fromEscherichia coli.Scand J Immun 10, 81 (1979).
Isenman D E, Dorrington K J, Painter R H: The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement.J Immun 114, 1726 (1975).
Wisloff F, Michaelsen T E, Froland S S: Inhibition of antibody-dependent human lymphocyte-mediated cytotoxicity by immunoglobulin classes, IgG subclasses, and IgG fragments.Scand J Immun 3, 29 (1974).
Kassel R L, Old L J, Carswell E, Fiore N, Hardy W D: Serum-mediated leukemia cell destruction in AKR mice. Role of complement in the phenomenon.J Exp Med 138, 925 (1973).
Hersey P: New look at antiserum therapy of leukaemia.Nature (New Biol) 244, 22 (1973).
Bernstein I D, Tam M R, Nowinski R C: Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.Science 207, 68 (1980).
Lanier L L, Babcock G F, Raybourne R B, Arnold L W, Warner N L, Haughton G: Mechanism of B-cell lymphoma immunotherapy with passive xenogeneic anti-idiotype serum.J Immun 125, 1730 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stevenson, G.T., Cole, V.M., Summerton, J. et al. Chimeric univalent antibodies for treating lymphoid malignancies. Med. Oncol. & Tumor Pharmacother. 1, 275–278 (1984). https://doi.org/10.1007/BF02934535
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02934535